{"id":16344,"date":"2022-09-30T11:06:45","date_gmt":"2022-09-30T10:06:45","guid":{"rendered":"https:\/\/touchrespiratory.com\/?post_type=media_gallery&p=16344"},"modified":"2022-09-30T11:15:36","modified_gmt":"2022-09-30T10:15:36","slug":"robin-deterding-ers-2022-findings-from-the-inpedild-trial","status":"publish","type":"media_gallery","link":"https:\/\/touchrespiratory.com\/interstitial-lung-disease\/conference-hub\/robin-deterding-ers-2022-findings-from-the-inpedild-trial\/","title":{"rendered":"Robin Deterding, ERS 2022: Findings from the InPedILD Trial"},"content":{"rendered":"

The InPedILD trial<\/a> was a phase 3, double-blind placebo-controlled trial investigating nintedanib in children and adolescents with fibrosing interstitial lung diseases (ClinicalTrials.gov: NCT04093024<\/a>). We were delighted to speak to Dr. Robin Deterding<\/strong> (University of Colorado; Children’s Hospital Colorado, Aurora, CO, USA) to discuss the aims, design, eligibility criteria and findings from the phase 3 study.<\/p>\n

The abstract ‘Nintedanib in children and adolescents with fibrosing interstitial lung disease: the InPedILD trial.<\/em>‘ was presented at ERS 2022<\/a>, 4\u20136 September, 2022.<\/p>\n

Questions<\/b><\/p>\n

    \n
  1. What were the aims, design and eligibility criteria of the InPedILD trial? (0:35)<\/li>\n
  2. What were the primary and secondary efficacy and safety endpoints, and how well were they achieved? (2:41)<\/li>\n
  3. On the basis of these findings, what further studies are planned? (7:43)<\/li>\n<\/ol>\n

    Disclosures:<\/b> Robin Deterding discloses consulting for Boehringer Ingelheim; receiving grant\/ research support from Boehringer Ingelheim; and serving on advisory boards for Boehringer Ingelheim.<\/p>\n

    Support:<\/b> Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.<\/p>\n

    Filmed in coverage of the ERS meeting 2022.<\/i><\/b><\/p>\n","protected":false},"excerpt":{"rendered":"

    The InPedILD trial was a phase 3, double-blind placebo-controlled trial investigating nintedanib in children and adolescents with fibrosing interstitial lung diseases (ClinicalTrials.gov: NCT04093024). We were delighted to speak to Dr. Robin Deterding (University of Colorado; Children’s Hospital Colorado, Aurora, CO, USA) to discuss the aims, design, eligibility criteria and findings from the phase 3 study. […]<\/p>\n","protected":false},"featured_media":16372,"template":"","class_list":["post-16344","media_gallery","type-media_gallery","status-publish","has-post-thumbnail","hentry","vocabulary_1-interstitial-lung-disease","vocabulary_1-paediatric-respiratory-medicine","video_categories-ers-highlights"],"acf":[],"_links":{"self":[{"href":"https:\/\/touchrespiratory.com\/wp-json\/wp\/v2\/media_gallery\/16344","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/touchrespiratory.com\/wp-json\/wp\/v2\/media_gallery"}],"about":[{"href":"https:\/\/touchrespiratory.com\/wp-json\/wp\/v2\/types\/media_gallery"}],"version-history":[{"count":13,"href":"https:\/\/touchrespiratory.com\/wp-json\/wp\/v2\/media_gallery\/16344\/revisions"}],"predecessor-version":[{"id":16686,"href":"https:\/\/touchrespiratory.com\/wp-json\/wp\/v2\/media_gallery\/16344\/revisions\/16686"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/touchrespiratory.com\/wp-json\/wp\/v2\/media\/16372"}],"wp:attachment":[{"href":"https:\/\/touchrespiratory.com\/wp-json\/wp\/v2\/media?parent=16344"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}